Expanding & De-Risking Radioligand Drug Discovery
Radioligand therapy is at a pivotal moment: investment is surging, clinical momentum is building, yet true innovation remains constrained by narrow target strategies and familiar isotope choices.
The 2nd TRP Target Selection & Drug Design Summit 2026 is the only meeting dedicated specifically to this challenge. Over three days, we are bringing together R&D leaders, radiochemists, biologists, and translational experts to advance the science and strategy behind next-generation radiopharmaceuticals. Through focused discussions and case-driven presentations, attendees will examine new target opportunities beyond PSMA and SSTR2, emerging isotope platforms, advances in targeting moiety engineering, and explore the risk level that should be taken when moving into novel RLT targets
With insights from Novartis, AstraZeneca, Abdera, Radiopharm Theranostics, PentixaPharm, Bicycle Therapeutics, and leading KOLs, the 2nd TRP Target Selection & Drug Design Summit strives to provide the perfect environment for evaluating the technologies & strategies that will shape the future of RLT, from target–isotope matching to preclinical dosimetry, and combination strategies to novel targets.
If you’re working to design smarter targeting moieties, navigate imperfect targets, expand the role of alpha and beta emitters, or translate dosimetry into more predictable in-human outcomes, this is the place where those conversations happen.
Join 100+ radiochemists, biologists, C-Level Leaders, and decision-makers shaping the next era of radiopharmaceutical innovation, and help to diversify pipelines, enable both therapeutic safety and efficacy, and move toward more specific, more effective, and more durable treatments for patients at the earliest stage of development.
While everyone came with a different perspective, there was a real sense that everyone was prepared to discuss the key issues facing our field in a productive manner.
Past Attendee, Director, AstraZeneca
I liked the balance of having both preclinical and clinical speakers that could give an overall picture of the challenges that come with RLTs.
Past Attendees, Senior Scientific Lead, ADME & DMPK, Eli Lilly
From my point of view speakers and companies attending the conference were very well picked. Also, the scope of the conference with a rather selected number of attendants generated a nice, familiar atmosphere. It gave a good possibility to connect with people in the field. Also, the talks were nicely picked and aligned in the conference program.
Past Attendees, Director, Program Management, PentixaPharm
Explore the Full Event Guide
- 100+ attendees from world-leading RLT companies
- 20+ expert speakers including Novartis, Bayer, AstraZeneca & Convergent Therapeutics
- 12+ C-Suite speakers with direct influence on their companies' pipelines
- 6+ novel targets explored, including PD-L1, DLL3, B7-H3, CEACAM5, KLK3 and COF-01
- 6+ Hours of Built-In Networking alongside pioneers in the RLT industry
- 3 Big Pharma Companies Presenting on the advancements in their RLT pipeline
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover how the field’s leaders are redefining target selection, isotope pairing, and translational strategy to unlock the next era of radioligand therapy.
Partner With Us
Connect with RLT decision-makers searching for partners in targeting, imaging, radiochemistry, and isotopes to drive faster, safer radiopharmaceutical development.
Join RLT Experts
Join 100+ radiochemists, biologists, drug designers, and R&D leaders advancing next-generation radioligand therapies from discovery through translation.